Type I Diabetes

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells in patients with early type 1 diabetes.

The results of a new study in mice show that early exposure to certain bacteria and fungus can give the immune system a boost and reduce the risk of type 1 diabetes.

Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.

In this part 2 video series, Arti Masturzo, M.D., chief medical officer of CCS, shares how coaching those with type 1 diabetes can deliver both measurable health improvements such as significant reductions in A1C levels, and enhanced patient confidence by providing hands-on education and support. Masturzo also addressed how CCS collaborates with healthcare providers and insurers to integrate care, reduce fragmentation and improve adherence to monitoring and treatment through AI-driven efforts.

Although the importance of ongoing education is known for patients, less than half of those with diabetes receive formal instruction on managing their condition.

COUR Pharmaceuticals is about begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.

In November 2024, a regulatory advisory board said the benefits of Zynquista does not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

New research suggests that activation of the PPARδ protein, which is linked to inflammation, could treat or prevent diabetic cardiomyopathy, a serious heart condition.

Patients with type 1 diabetes were more likely to be prescribed continuous glucose monitoring compared with those with type 2 diabetes, a new analysis finds.

A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain development and cognitive function, focusing on diverse participants and paving the way for early interventions and better diabetes management.

An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped adolescents experience less distress and improved self-management behavior.

Early research shows the CD40L antibody tegoprubart is able to reduce insulin dependence in patients with type 1 diabetes after islet transplants.

A clinical trial in the United Kingdom has found that Stelara may help to reduce the level of a type of immune cell, which appears to play a role in destroying insulin-producing cells.

Type 1 diabetes is a relentless disease, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in type 1 diabetes treatment, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

David Maahs, M.D., M.A., Ph.D., explains why teamwork is the most important part of the 4T diabetes management program.

David Maahs, M.D., M.A., Ph.D., explains the role that teamwork, targets, technology and tight control plays in type 1 diabetes management and why it’s best to intervene right after diagnosis.

A study in mice finds that blocking somatostatin could restore the ability of the pancreas to release glucagon in the event of low blood sugar.

VX-880 is an allogeneic stem cell-derived islet cell therapy that has been able to control blood glucose as well as natural human islets in a small group of patients with type 1 diabetes.

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic events than patients taking insulin degludec.

The Type 1 Diabetes Grand Challenge has provided awards to six universities —including three in the United States — to fund research of novel therapies to treat patients with type 1 diabetes.

A new study finds that diabetes and mental health are linked. People with chronic diabetes complications are at a three-times greater risk of having a mental health condition.

New research looks at the impact of state-level caps on out-of-pocket costs for insulin. Before the caps, most commercial enrollees were already paying costs below the cap amounts.

Medicaid children with type 1 diabetes are three times more likely to receive metformin than commercial enrollees even though metformin is only indicated for use in patients with type 2 diabetes.

As many as 40% of people with type 1 diabetes are unaware that they have the disease.

The FDA is asking for information about the manufacturing process, as well as the type 1 diabetes indication.

Findings from observational studies in the past have not been consistent on the link between type 1 diabetes and epilepsy.